These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 28775928)

  • 41. The outcomes of concomitant radiation plus temozolomide followed by adjuvant temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study.
    Shawky H; Abo Hamar AH; Galal S; Zakaria F; El-Shorbagy D
    J Egypt Natl Canc Inst; 2009 Jun; 21(2):107-19. PubMed ID: 21057562
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
    Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R;
    Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma.
    Wang TJC; Wu CC; Jani A; Estrada J; Ung T; Chow DS; Soun JE; Saad S; Qureshi YH; Gartrell R; Saadatmand HJ; Saraf A; Garrett MD; Grubb C; Isaacson SR; Cheng SK; Sisti MB; Bruce JN; Sheth SA; Lassman AB; Iwamoto FM; McKhann GM
    Pract Radiat Oncol; 2016; 6(5):306-314. PubMed ID: 26952813
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fractionated stereotactic radiotherapy plus bevacizumab after response to bevacizumab plus irinotecan as a rescue treatment for high-grade gliomas.
    Conde-Moreno AJ; García-Gómez R; Albert-Antequera M; Almendros-Blanco P; De Las Peñas-Bataller R; González-Vidal V; López-Torrecilla JL; Ferrer-Albiach C
    Rep Pract Oncol Radiother; 2015; 20(3):231-8. PubMed ID: 25949228
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcomes in Elderly Patients with Glioblastoma Multiforme Treated with Short-Course Radiation Alone Compared to Short-Course Radiation and Concurrent and Adjuvant Temozolomide Based on Performance Status and Extent of Resection.
    Mir T; Pond G; Greenspoon JN
    Curr Oncol; 2021 Jun; 28(4):2399-2408. PubMed ID: 34206775
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series.
    Navarria P; Pessina F; Clerici E; Rossini Z; Franceschini D; D'Agostino G; Franzese C; Comito T; Loi M; Simonelli M; Lorenzi E; Persico P; Politi LS; Grimaldi M; Bello L; Santoro A; Fornari M; Servadei F; Scorsetti M
    J Neurosurg; 2021 Jul; 135(1):64-77. PubMed ID: 32886916
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience.
    Jablonska PA; Diez-Valle R; Pérez-Larraya JG; Moreno-Jiménez M; Idoate MÁ; Arbea L; Tejada S; Garcia de Eulate MR; Ramos L; Arbizu J; Domínguez P; Aristu JJ
    PLoS One; 2019; 14(6):e0217881. PubMed ID: 31170245
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
    Minniti G; Scaringi C; Lanzetta G; Terrenato I; Esposito V; Arcella A; Pace A; Giangaspero F; Bozzao A; Enrici RM
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):109-15. PubMed ID: 25442339
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Extent of surgical resection and adjuvant temozolomide improves survival in pediatric GBM: a single center experience.
    Gupta S; Mallick S; Benson R; Haresh KP; Julka PK; Rath GK
    Childs Nerv Syst; 2017 Jun; 33(6):951-956. PubMed ID: 28424876
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
    Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
    J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
    Iuchi T; Hatano K; Kodama T; Sakaida T; Yokoi S; Kawasaki K; Hasegawa Y; Hara R
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):793-800. PubMed ID: 24495592
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
    Younis SG; Khedr RA; El-Shorbagy SH
    J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
    Herrlinger U; Rieger J; Koch D; Loeser S; Blaschke B; Kortmann RD; Steinbach JP; Hundsberger T; Wick W; Meyermann R; Tan TC; Sommer C; Bamberg M; Reifenberger G; Weller M
    J Clin Oncol; 2006 Sep; 24(27):4412-7. PubMed ID: 16983109
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
    Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
    Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma.
    Yusuf M; Ugiliweneza B; Amsbaugh M; Boakye M; Williams B; Nelson M; Hattab EM; Woo S; Burton E
    Oncology; 2018; 95(1):39-42. PubMed ID: 29694955
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
    Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
    Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma.
    Fine H; Reid T; Caroen S; Oronsky B; Abrouk N; Butowski N
    Front Oncol; 2023; 13():1176448. PubMed ID: 37342189
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.
    Badiyan SN; Markovina S; Simpson JR; Robinson CG; DeWees T; Tran DD; Linette G; Jalalizadeh R; Dacey R; Rich KM; Chicoine MR; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):877-85. PubMed ID: 25257812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.